PDCD1 and pancreatic neoplasm: The MTD was 700 mg/day (4 days on/10 days off) for BLZ945 + spartalizumab (anti-PD-1 antibody) in patients having cancers with upregulated TAMs including GBM and pancreatic cancer [51].